Expert: Anti-CD40 ligand PEGylated antigen-binding fragment that blocks CD40L-CD40 interaction, inhibiting T cell-dependent B cell activation and reducing autoimmune inflammation.

Everyday: Blocks CD40L, a protein that activates immune cells and causes inflammation in autoimmune diseases.

Targets: ["CD40L"]

Primary EP: [{"id":"ep1","name":"BICLA response at Week 48","type":"PRIMARY","unit":"%","results":[{"n":208,"arm":"DZP + SOC","value":49.5,"detail":"103/208 responders"},{"n":107,"arm":"Placebo + SOC","value":34.

Safety: Generally well-tolerated. TEAEs slightly higher in DZP arm (82.6% vs 75.0%) but serious TEAEs actually lower (9.9% vs 14.8%). Key safety signal: opportunistic infections (2.8% vs 0.9%) and 1 thromboem

Primary EP: [{"id":"ep1","name":"BICLA response at Week 48","type":"PRIMARY","unit":"%","results":[],"timepoint":"Week 48","description":"Same primary as PHOENYCS GO. BICLA composite assessing lupus disease activ

Dapirolizumab Pegol - SLE - Ph3 - Topline (PHOENYCS FLY) 2027-2028

PEGylated anti-CD40 ligand (CD40L) Fab' fragment for systemic lupus erythematosus. Blocks costimulatory pathway critical for autoimmune activation; PEGylation reduces thromboembolic risk seen with earlier anti-CD40L antibodies.